A simple, reliable and rapid isocratic liquid chromatography(LC)-mass spectrometric detection(MS) coupled with electrospray ionization(ESI) method for simultaneous separation and determination of calycosin-7-O-β-D-gl...A simple, reliable and rapid isocratic liquid chromatography(LC)-mass spectrometric detection(MS) coupled with electrospray ionization(ESI) method for simultaneous separation and determination of calycosin-7-O-β-D-glucoside, ononin, calycosin and formonometin in Astragali Radix was developed. After the samples were extracted with ethanol, the optimum separation conditions for these analytes were achieved using water and acetonitrile(70:30, v/v) containing 0.2%(v/v) acetic acid as a mobile phase and a 2.0 mm×150 mm Hypersil-Keystone C18 column. Selective ion monitoring(SIM) mode and [M+H]+ ions at m/z 447, 431, 285 and 269 were used for quantitative analysis of four main active components above mentioned. The calibration curves were linear in the range of 0.4-175.0 μg/mL for calycosin-7-O-β-D-glucoside, 0.2-146.0 μg/m L for ononin, 0.4-210.0 μg/mL for calycosin and 0.5-217.0 μg/mL for formonetion, respectively. The limits of quantification(LOQ) and detection(LOD) were 0.4 μg/mL and 0.08 μg/m L for calycosin-7-O-β-D-glucoside, 0.2 μg/mL and 0.06 μg/m L for ononin, 0.4 μg/mL and 0.1 μg/mL for calycosin, 0.5 μg/m L and 0.1 μg/m L formonetion, respectively. The standard recoveries were in the range of 96.5%-104.7%. The developed method has successfully been used for the determination of four main flavonoids in Astragali Radix from various sources and can be used for identification, differentiation and quality evaluation of Astragali Radix.展开更多
基于网络药理学、分子对接及实验验证探究中药药对黄芪-党参(Astragali Radix-Codonopsis Radix,AR-CR)治疗动脉粥样硬化(atherosclerosis,AS)的分子作用机制。首先通过检索TCMSP、PubChem、SwissTargetPrediction、UniProt、GeneCards...基于网络药理学、分子对接及实验验证探究中药药对黄芪-党参(Astragali Radix-Codonopsis Radix,AR-CR)治疗动脉粥样硬化(atherosclerosis,AS)的分子作用机制。首先通过检索TCMSP、PubChem、SwissTargetPrediction、UniProt、GeneCards等数据库,获取中药药对AR-CR的活性成分,预测该药对的作用靶点,筛选动脉粥样硬化的相关靶点基因,然后利用Venny平台、STRING数据库、Cytoscape(Version 3.8.2)软件进行拓扑分析获取AR-CR治疗动脉粥样硬化的关键靶点,使用DAVID数据库对所获得的关键靶点进行GO和KEGG富集分析,并借助Auto Dock tools、Auto Dock cina对核心蛋白与活性成分完成分子对接,最后,利用氧化型低密度脂蛋白(oxidized low density lipoprotein,ox-LDL)诱导人脐静脉内皮细胞,建立AS细胞模型进行体外生物学验证。AR-CR共检索到34个活性化合物,并预测潜在化合物靶点426个,通过与875个AS靶点进行交际映射,获得AR-CR治疗AS关键靶点69个,筛选出3,9-二邻甲基苯胺、7-甲氧基-2-甲基异黄酮、5α-豆甾烷-3,6-二酮、木犀草素4个主要活性化合物,丝氨酸/苏氨酸蛋白激酶(serine/threonine-protein kinase,AKT1)、肿瘤蛋白p53(tumor protein p53,TP53)、丝裂原激活蛋白激酶3(mitogen-activated protein kinase 3,MAPK3)等25个核心靶点。KEGG通路富集分析得到关键通路为糖基化终末产物(advanced glycation end-product,AGE)/糖基化终末产物受体(receptor for advanced glycation endproduct,RAGE)信号通路和脂质与动脉粥样硬化信号通路等。分子对接结果显示4个主要活性化合物与核心靶点蛋白均能连接,其中与TP53的结合活性最强。体外实验结果表明低、中、高剂量的AR-CR能够促进动脉粥样硬化模型细胞增殖,抑制其凋亡,并促进TP53 mRNA及TP53蛋白表达。综上,该研究初步揭示AR-CR治疗AS的作用机制,与网络药理学及分子对接预测的TP53因子相关,通过调控TP53因子促进AS模型细胞增殖,抑制其凋亡,为临床治疗AS提供了理论基础。展开更多
基金Project(21472110)supported by the National Natural Science Foundation of ChinaProject(LY15B050008)supported by the Natural Science Foundation of Zhejiang Province,ChinaProject(2013Y003)supported by Quzhou Technology Projects,China
文摘A simple, reliable and rapid isocratic liquid chromatography(LC)-mass spectrometric detection(MS) coupled with electrospray ionization(ESI) method for simultaneous separation and determination of calycosin-7-O-β-D-glucoside, ononin, calycosin and formonometin in Astragali Radix was developed. After the samples were extracted with ethanol, the optimum separation conditions for these analytes were achieved using water and acetonitrile(70:30, v/v) containing 0.2%(v/v) acetic acid as a mobile phase and a 2.0 mm×150 mm Hypersil-Keystone C18 column. Selective ion monitoring(SIM) mode and [M+H]+ ions at m/z 447, 431, 285 and 269 were used for quantitative analysis of four main active components above mentioned. The calibration curves were linear in the range of 0.4-175.0 μg/mL for calycosin-7-O-β-D-glucoside, 0.2-146.0 μg/m L for ononin, 0.4-210.0 μg/mL for calycosin and 0.5-217.0 μg/mL for formonetion, respectively. The limits of quantification(LOQ) and detection(LOD) were 0.4 μg/mL and 0.08 μg/m L for calycosin-7-O-β-D-glucoside, 0.2 μg/mL and 0.06 μg/m L for ononin, 0.4 μg/mL and 0.1 μg/mL for calycosin, 0.5 μg/m L and 0.1 μg/m L formonetion, respectively. The standard recoveries were in the range of 96.5%-104.7%. The developed method has successfully been used for the determination of four main flavonoids in Astragali Radix from various sources and can be used for identification, differentiation and quality evaluation of Astragali Radix.
文摘基于网络药理学、分子对接及实验验证探究中药药对黄芪-党参(Astragali Radix-Codonopsis Radix,AR-CR)治疗动脉粥样硬化(atherosclerosis,AS)的分子作用机制。首先通过检索TCMSP、PubChem、SwissTargetPrediction、UniProt、GeneCards等数据库,获取中药药对AR-CR的活性成分,预测该药对的作用靶点,筛选动脉粥样硬化的相关靶点基因,然后利用Venny平台、STRING数据库、Cytoscape(Version 3.8.2)软件进行拓扑分析获取AR-CR治疗动脉粥样硬化的关键靶点,使用DAVID数据库对所获得的关键靶点进行GO和KEGG富集分析,并借助Auto Dock tools、Auto Dock cina对核心蛋白与活性成分完成分子对接,最后,利用氧化型低密度脂蛋白(oxidized low density lipoprotein,ox-LDL)诱导人脐静脉内皮细胞,建立AS细胞模型进行体外生物学验证。AR-CR共检索到34个活性化合物,并预测潜在化合物靶点426个,通过与875个AS靶点进行交际映射,获得AR-CR治疗AS关键靶点69个,筛选出3,9-二邻甲基苯胺、7-甲氧基-2-甲基异黄酮、5α-豆甾烷-3,6-二酮、木犀草素4个主要活性化合物,丝氨酸/苏氨酸蛋白激酶(serine/threonine-protein kinase,AKT1)、肿瘤蛋白p53(tumor protein p53,TP53)、丝裂原激活蛋白激酶3(mitogen-activated protein kinase 3,MAPK3)等25个核心靶点。KEGG通路富集分析得到关键通路为糖基化终末产物(advanced glycation end-product,AGE)/糖基化终末产物受体(receptor for advanced glycation endproduct,RAGE)信号通路和脂质与动脉粥样硬化信号通路等。分子对接结果显示4个主要活性化合物与核心靶点蛋白均能连接,其中与TP53的结合活性最强。体外实验结果表明低、中、高剂量的AR-CR能够促进动脉粥样硬化模型细胞增殖,抑制其凋亡,并促进TP53 mRNA及TP53蛋白表达。综上,该研究初步揭示AR-CR治疗AS的作用机制,与网络药理学及分子对接预测的TP53因子相关,通过调控TP53因子促进AS模型细胞增殖,抑制其凋亡,为临床治疗AS提供了理论基础。
